International Myeloma Society Educational Workshop

Overview

The International Myeloma Society (IMS) Educational Workshop is an advanced educational program dedicated to the diagnosis, treatment, monitoring, and long-term management of multiple myeloma and related plasma cell disorders. Combining evidence-based lectures with interactive panel discussions and case-based learning, the workshop explores current standards of care, emerging therapies, and evolving clinical practices in the management of plasma cell malignancies.

Designed to address both established and controversial topics, the program encourages critical discussion through expert perspectives, challenging clinical scenarios, and practical applications that help clinicians optimize patient outcomes across the continuum of care.

---

Course Highlights

• Comprehensive review of contemporary multiple myeloma diagnosis and management
• Updates on diagnostic testing, imaging, and minimal residual disease (MRD) assessment
• Evidence-based treatment strategies for newly diagnosed, smoldering, relapsed, and refractory multiple myeloma
• In-depth coverage of novel immunotherapies, including CAR T-cell therapy and bispecific antibodies
• Practical guidance for sequencing therapies throughout disease progression
• Management of myeloma-related complications and complex clinical cases
• Interactive case discussions focused on challenging treatment decisions
• Coverage of related plasma cell disorders, including AL amyloidosis and Waldenström's macroglobulinemia

---

Learning Objectives

Upon completion of this workshop, participants should be able to:

• Evaluate current diagnostic approaches, imaging techniques, minimal residual disease (MRD) testing, and risk stratification models for multiple myeloma.
• Apply evidence-based management strategies for smoldering multiple myeloma and newly diagnosed multiple myeloma in both transplant-eligible and transplant-ineligible patients.
• Develop treatment sequencing strategies for relapsed and refractory multiple myeloma.
• Integrate novel immunotherapies, including CAR T-cell therapies and bispecific T-cell engagers, into clinical practice.
• Effectively manage common myeloma-related complications, including bone disease, renal impairment, and treatment-related infections.
• Formulate treatment plans for complex clinical presentations such as extramedullary disease, plasma cell leukemia, frailty, and relapse following T-cell redirected therapies.
• Recognize and manage related plasma cell disorders, including Waldenström's macroglobulinemia and AL amyloidosis.

---

Course Content

Advances in Multiple Myeloma

• The future of multiple myeloma treatment
• Progress toward curative therapies
• Emerging clinical developments

Diagnosis and Risk Stratification

• Diagnostic evaluation of multiple myeloma
• Imaging techniques and recommendations
• Minimal Residual Disease (MRD) testing
• Risk stratification models
• Monitoring and long-term follow-up

Smoldering and Newly Diagnosed Multiple Myeloma

• Management of smoldering multiple myeloma
• Treatment strategies for transplant-eligible patients
• Treatment strategies for transplant-ineligible patients
• Evidence-based therapeutic decision-making

Relapsed and Refractory Multiple Myeloma

• Treatment sequencing for first and second relapse
• Optimizing therapy selection
• Management of relapsed and refractory disease

Novel Immunotherapies

• CAR T-cell therapy
• Bispecific T-cell engagers
• Emerging targeted therapies beyond cellular therapies
• Integration of new immunotherapies into clinical practice

Management of Myeloma-Related Complications

• Bone disease
• Renal impairment
• Infection prevention and vaccination
• Supportive care strategies

Related Plasma Cell Disorders

• Waldenström's macroglobulinemia
• AL amyloidosis
• Diagnosis and management of other dysproteinemias

Challenging Clinical Scenarios

• Relapse after T-cell redirected therapies
• Extramedullary disease
• Plasma cell leukemia
• Frailty assessment and individualized treatment planning
• Management of complex multiple myeloma cases

Interactive Clinical Discussions

• Diagnosis and patient follow-up
• Management of smoldering and newly diagnosed disease
• Therapy sequencing in relapsed disease
• Clinical implementation of novel immunotherapies
• Management of treatment-related complications
• Challenging and controversial cases in multiple myeloma

---

Intended Audience

This educational workshop is intended for:

• Hematologists
• Medical oncologists
• Nephrologists
• Infectious disease specialists
• Clinical investigators
• Research scientists
• Fellows and trainees in hematology and oncology
• Healthcare professionals involved in the diagnosis and management of plasma cell disorders

The program is ideal for clinicians seeking to remain current with advances in multiple myeloma, integrate emerging therapies into practice, and improve evidence-based, patient-centered care for plasma cell malignancies.